Clinical Trial Detail

NCT ID NCT02331251
Title Study of Pembrolizumab Plus Chemotherapy in Patients With Advanced Cancer (PembroPlus)
Recruitment Terminated
Gender both
Phase Phase Ib/II
Variant Requirements no
Sponsors Western Regional Medical Center
Indications

lung small cell carcinoma

pancreatic adenocarcinoma

sarcoma

Advanced Solid Tumor

Therapies

Vinorelbine

Pembrolizumab

Irinotecan

Doxorubicin

Gemcitabine

Docetaxel

Nab-paclitaxel

Age Groups: adult

No variant requirements are available.